Maraviroc

Medical Advocates
Maraviroc (Selzentry)

Main Page

New and Noteworthy
Journal Data
Conference Data

FDA/EU Approvals
Product Information

Perinatal

ARV Drugs Main Page

Main New/Newsworthy

Home Page

This web page is best viewed by using INTERNET EXPLORER
Last Update: April 25, 2018
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

April 2018

Towards a Maraviroc Long-Acting Injectable Nanoformulation.
Tatham LM, Savage AC, Dwyer A, et al Eur J Pharm Biopharm. 2018 Apr 20

Perinatal

Placental transfer of maraviroc in the ex vivo human cotyledon perfusion model and influence of ABC transporter expression.
Vinot C, Gavard L, Tréluyer JM, et al
Antimicrob Agents Chemother. 2013 Jan 7.
Abstract
Genotypic and functional properties of early infant HIV-1 envelopes.
Kishko M, Somasundaran M, Brewster F, et al
Retrovirology. 2011 Aug 15;8(1):67.
Abstract

Pediatric

A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses.
Khandelwal P, Fukuda T, Mizuno K, et alBiol Blood Marrow Transplant. 2016 Aug 3
Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice.
Palladino C, Gómez ML, Soler-Palacín P, et al AIDS. 2015 Oct 23;29(16):2155-2159.

ARV Drugs Main Page

Main New/Newsworthy

Home Page

Maraviroc (Selzentry) Main Page